Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthijs M Versteegh

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Multiple Sclerosis and Related Disorders|July 27, 2025
Exit strategies in patients with stable MS: Cost-effectiveness of extended interval dosing of ocrelizumab and natalizumab versus de-escalating to cladribineMatthijs M Versteegh, Simone A Huygens
Health Economics|December 12, 2012
Would you rather be ill now, or later?Arthur E Attema, Matthijs M Versteegh
Health Economics|April 27, 2022
Correcting for discounting and loss aversion in composite time trade-offStefan A Lipman, Arthur E Attema, Matthijs M Versteegh
Pharmacoeconomics|August 29, 2018
Estimating Informal Caregiving Time from Patient EQ-5D Data: The Informal CARE Effect (iCARE) ToolMaria Gheorghe, Renske J Hoefman, Matthijs M Versteegh, et al.
Health and Quality of Life Outcomes|November 30, 2010
Mapping onto Eq-5 D for patients in poor healthMatthijs M Versteegh, Donna Rowen, John E Brazier, et al.
Nederlands Tijdschrift Voor Geneeskunde|April 5, 2019
[Loss is gain? Discarding TNF-α inhibitors]Matthijs M Versteegh, Arthur E Attema, Carin A Uyl-de Groot
Advances in Therapy|July 13, 2023
Societal Utilities for Cognitive Impairment in Schizophrenia: Developing a Preference-Based Scoring Algorithm Based on the Schizophrenia Cognition Rating ScaleIrene Santi, Andrew J Lloyd, Claudia E Hastedt, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|August 1, 2013
Time trade-off: one methodology, different methodsArthur E Attema, Yvette Edelaar-Peeters, Matthijs M Versteegh, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|August 1, 2013
Introducing the composite time trade-off: a test of feasibility and face validityBas M F Janssen, Mark Oppe, Matthijs M Versteegh, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 6, 2022
Effectiveness and Cost-Effectiveness of 360 Disease-Modifying Treatment Escalation Sequences in Multiple SclerosisMatthijs M Versteegh, Simone A Huygens, Beatrijs W H Wokke, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Multiple Sclerosis and Related Disorders|July 27, 2025
Exit strategies in patients with stable MS: Cost-effectiveness of extended interval dosing of ocrelizumab and natalizumab versus de-escalating to cladribineMatthijs M Versteegh, Simone A Huygens
Health Economics|December 12, 2012
Would you rather be ill now, or later?Arthur E Attema, Matthijs M Versteegh
Health Economics|April 27, 2022
Correcting for discounting and loss aversion in composite time trade-offStefan A Lipman, Arthur E Attema, Matthijs M Versteegh
Pharmacoeconomics|August 29, 2018
Estimating Informal Caregiving Time from Patient EQ-5D Data: The Informal CARE Effect (iCARE) ToolMaria Gheorghe, Renske J Hoefman, Matthijs M Versteegh, et al.
Health and Quality of Life Outcomes|November 30, 2010
Mapping onto Eq-5 D for patients in poor healthMatthijs M Versteegh, Donna Rowen, John E Brazier, et al.
Nederlands Tijdschrift Voor Geneeskunde|April 5, 2019
[Loss is gain? Discarding TNF-α inhibitors]Matthijs M Versteegh, Arthur E Attema, Carin A Uyl-de Groot
Advances in Therapy|July 13, 2023
Societal Utilities for Cognitive Impairment in Schizophrenia: Developing a Preference-Based Scoring Algorithm Based on the Schizophrenia Cognition Rating ScaleIrene Santi, Andrew J Lloyd, Claudia E Hastedt, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|August 1, 2013
Time trade-off: one methodology, different methodsArthur E Attema, Yvette Edelaar-Peeters, Matthijs M Versteegh, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|August 1, 2013
Introducing the composite time trade-off: a test of feasibility and face validityBas M F Janssen, Mark Oppe, Matthijs M Versteegh, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 6, 2022
Effectiveness and Cost-Effectiveness of 360 Disease-Modifying Treatment Escalation Sequences in Multiple SclerosisMatthijs M Versteegh, Simone A Huygens, Beatrijs W H Wokke, et al.
Pageof 3